Dr Jing Yang TeeBBiotech (Hons), PhD
Principal Scientist
PhD at Griffith University where he uncovered biological deficits to cell movement in olfactory stem cells from people with schizophrenia. In 2021 he joined Shenzhen Bay Laboratory in China and in 2022, he completed a short R&D stint at a new start-up biotech company in Shenzhen working on early discovery of immunotherapies. In 2023, he returned to Shenzhen Bay Laboratory to work on potent small molecule inhibitors that the target cancer cell cycle and small molecule degraders for misfolded proteins in Alzheimer’s Disease. In late 2024, he returned to Australia to start a scientist role at Cartherics and now with Evinco Therapeutics, working on developing immunotherapies for neurological disorders such as Alzheimer’s Disease.
Dr Andrew FrenchBAgSc (Hons), PhD
Senior Researcher/Scientific Consultant
Andrew French is a senior biotechnology and translational research executive with more than 30 years of global experience advancing innovative biomedical technologies. His career spans reproductive science, regenerative medicine, cancer and neurodegenerative therapeutics, embryology, fertility, and stem cell applications.
Andrew specialises in guiding programs from early discovery through clinical development, with expertise in research design, biomedical diligence, IP strategy, and commercialisation. He has worked extensively across Australia, New Zealand, Hong Kong, Mainland China, the United States, Singapore, Chile, and Uruguay, building strong cross‑border partnerships and navigating diverse regulatory environments.
As a consultant, Andrew has advised over fifty organisations—including leading hospitals, universities, biotech companies, and government agencies—supporting product development, translational strategy, and technology commercialisation.
Dr Richard BoydBSc (Hons), PhD
Scientific Consultant
Professor of Immunology, Monash University
Co-founder, Cartherics Pty Ltd
Professor of Immunology at Monash University, Dr Richard Boyd is an expert in the nature and function of the thymus microenvironment for forming T cells from blood stem cells and pioneer of clinical trials to boost the T cell-based immune system in cancer patients through rejuvenation of the thymus.
Prof Alice Pébay AMBSc (Psych), PhD
Scientific Consultant Dame Kate Campbell Fellow, University of Melbourne
Prof. Alice Pébay AM earned her PhD in Neurosciences from the Universit Pierre et Marie Curie (Paris) in 2001. Prof. Pébay’s research focuses on using patient-specific pluripotent stem cells to model neurodegenerative diseases of the eye and brain. She has an established track record in generating induced pluripotent stem cells (iPSCs) and differentiating them into various cell types for disease modelling, particularly for conditions affecting the central nervous system and the eye.
Dr Peter HudsonFTSE, BSc (Hons), PhD
Scientific Advisor, Co-founder, Cartherics Pty Ltd
Co-founder, Cartherics Pty Ltd
Peter Hudson is a co-founder of Cartherics Pty Ltd, advising on Car-T and iNK molecular designs and IP strategy. A molecular biologist with a PhD from Cambridge, he has held senior research roles at CSIRO, co-founded multiple biotech companies, and led innovations in antibody-based therapeutics. He has authored over 140 publications, holds 30 patents, and has received several prestigious scientific awards.
Dr Karl TrounsonBSc, BSpExSc (Hons), PhD
Scientific Advisor
Karl Trounson holds a PhD from Victoria University and a Bachelor of Science from the University of Melbourne. He has published research spanning biomechanics, exercise physiology, and neuroscience. Karl has a unique mix of work experience, holding senior applied sport science roles with organisations such as the Richmond Football Club, Basketball Australia, and the Brooklyn Nets, as well as biomedical research roles at the Walter and Eliza Hall Institute and the Florey Institute of Neuroscience and Mental Health. At Evinco, he advises on research strategy to evaluate the potential of NK-cell extracellular vesicles to modulate neuroinflammation and improve outcomes following concussion, helping bridge preclinical neuroscience with real-world neurological injury models relevant to contact sport.
Mrs Jill McFadyean
Executive Assistant and Company Secretary
Jill has more than 35 years’ experience as an Executive Assistant, predominantly in the University sector.
Ms Alexandra TurnerBSc (Hons)
Research Assistant
Alexandra Turner is a Research Assistant at Evinco Therapeutics with a background in immunology and cancer biology. She now applies this expertise in the R&D team, working collaboratively to advance research into neuroinflammatory diseases.
Dr Christine FilippisBSc (Hons), PhD
Communications Director
Christine is an experienced communications specialist with expertise across corporate communications, PR, media, and investor relations. She has worked with clients spanning engineering and infrastructure, sustainability, mining, technology, health, and biotechnology, consistently delivering effective communication strategies.
Dr Inbar Amit AvrahamBSc (Hons), PhD
Biotechnology Consultant
Dr Inbar Amit Avraham is a senior biotechnology executive with more than 15 years of experience in therapeutic antibody research and development. She has a strong track record of advancing biologic products from discovery through clinical development and commercialisation, while building and leading global R&D teams. At Evinco, Inbar provides strategic guidance on drug discovery, translational development and portfolio strategy to support the successful delivery of innovative therapies to patients.